Author(s)

Yan Li, Nathaniel P. Reuter, Xuanshe Li, Robert Calvin Grier Martin

.
Division of Surgical Oncology, Department of Surgery, University of Louisville School of Medicine, Louisville, USA.

We aim to test the hypothesis that Con A-induced hepatitis and cell death can be prevented by the administration of the MnSOD mimetic MnTBAP. Male C57 mice were divided into 3 groups, 1) pretreated with MnTBAP (30 mg/kg) for 2 days and then Concanavalin A (Con A) (15 mg/kg); 2) pretreated with saline for 2 days and then Con A (15 mg/kg); 3) was the control treated with saline for 3 days. Extensive hepatic necrosis, with a significant increase in apoptosis, lipid peroxidation and decreased MnSOD enzymatic activity was found in the hepatic tissue of Con A-treated mice with significantly attenuation of all factors by pretreatment with MnTBAP. MnTBAP protected hepatocytes from Con A-induced hepatic injury with less degree of liver inflammation—ConA + MnTBAP (2.1 ± 0.4) vs. Con A (2.6 ± 0.3)—and significantly less cell death (1.2 ± 0.3 vs. 2.7 ± 0.4, p = 0.03). MnSOD supplementation attenuated the oxidative-induced stress effects of Con A-induced injury and the protective effects of MnSOD supplementation against Con A-induced hepatitis could be through its anti-oxidative properties. Further evaluation of MnSOD manipulation could have the potential to prevent ongoing hepatic injury in hepatitis.

Carcinogenesis, Hepatocellular Carcinoma, Chemoprevention, Mntbap

Y. Li, N. Reuter, X. Li and R. Martin, "Manganese Superoxide Dismutase Therapy in a Murine Hepatitis-Associated Injury," Journal of Cancer Therapy, Vol. 2 No. 3, 2011, pp. 431-440. doi: 10.4236/jct.2011.23058.